Skip to content

iCare HOME2 Clinical Trial

iCare HOME2 Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05162989
Enrollment
47
Registered
2021-12-20
Start date
2021-11-26
Completion date
2021-12-15
Last updated
2021-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Intraocular Pressure

Brief summary

The aim of this clinical study is to provide information about the variability of the intraocular pressure (IOP) self-measurements with the iCare HOME2 tonometer in comparison to the variability of the IOP measurements with the reference tonometer (iCare IC200), over a wide range of IOP values.

Detailed description

The clinical study is planned to estimate the variability of the IOP measurement of iCare HOME2 and IC200. In the study, the subjects will learn to operate the iCare HOME2 tonometer independently by using the labeling materials provided to them. Once they learn to operate the tonometer, subjects will take three self-measurements on the selected eye both in sitting and supine position. The variability of the measurement results taken with iCare HOME2 will be compared to the variability of the measurement results taken with iCare IC200 by using the recorded results from the study subjects.

Interventions

DEVICEiCare HOME2 vs iCare IC200

Measurement of IOP with iCare HOME2 compared with iCare IC200.

Sponsors

Icare Finland Oy
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

Investigator cannot see both the test device and reference device measurement results.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Glaucoma patients having confirmed optic nerve damage with visual field defects consistent with the glaucomatous optic neuropathy or * Glaucoma-suspects being followed because of elevated IOP, and/or because of other risk factors for developing glaucoma or optic nerve damage.

Exclusion criteria

* Active ocular infection (e.g., pink eye or infectious conjunctivitis) * Recent trauma to the eye including corneal laceration or corneal/scleral perforation * Disabling arthritis or difficulty handling the tonometer * Severe difficulty in opening the eyes including abnormal contractions or twitches of the eyelid (blepharospasm) * Involuntary, rapid, and repetitive eye movements (nystagmus) * Low uncorrected near visual acuity of 20/200 or below * Significant glaucomatous central field loss * Only one functional eye * Poor or off-center visual fixation * Poor hearing and/or communicates using sign language * Keratoconus (or other corneal disorder) * Congenitally small eye (microphthalmos) * Enlarged eyeball from the childhood glaucoma (buphthalmos) * Previous experience using or interacting with the HOME tonometer during usability tests or clinical trials * Any affiliation with Icare and its employees * High corneal astigmatism (\>3d) * History of prior invasive corneal surgery including corneal laser surgery less than six months ago (e.g., LASIK, LASEK, Smile) * Corneal scarring * Very thick or very thin corneas (central corneal thickness greater than 600 μm or less than 500 μm) * Cataract extraction within the last 2 months * Wearing contact lenses during the study

Design outcomes

Primary

MeasureTime frameDescription
Repeatability of IOP measurementsThrough study completion, an average of 1-2 monthsRepeatability of IOP measurements comparison of iCare HOME2 vs iCare IC200

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026